Alan L. Landay, PhD

Alan L. Landay, PhD

Rush Medical College

Professor of Immunology/Microbiology and Medicine
Rush Medical College
Rush-Presbyterian-Saint Luke’s Medical Center
Chicago, Illinois

Committees and Organizations

  • Chair, OAR AIDS Pathogenesis Committee
  • Member, AmFar Review Panel
  • Member, NIH Vaccine Study Section
  • Member, Immune Based Therapy Committee ACTG

Honors and Awards

  • Visiting Professor, University of Puerto Rico
  • Visiting Professor, University of Southern California
  • Visiting Professor, Emory University
  • Visiting Professor, University New South Wales, Sydney, Australia


  • Pennsylvania State University, BS (1976)
  • University of Pittsburgh, PhD (1981)
  • University of Alabama, Birmingham, Postdoctoral Fellow

Selected Publications

  1. Tenorio AR, Smith KY, Kuritzkes D, Young R, Bremer J, Wrin T, Pepropoulous C, Shott S, Landay A, Kessler HA. HIV-1 infected antiretroviral-treated patients with prolonged partial viral suppression: Clinical, virologic and immunologic course. JAIDS. 2003;34(5):491-496.
  2. Jacobson JM, Lederman MM, Spritzler J, Valdez H, Tebas P, Skowron G, Wang R, Jackson JB, Fox L, Landay A, Gilbert MJ, O’Neil D, Bancroft L, Al-Harthi L, Jacobson MA, Merigan TC, Jr., Glesby MJ, and the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma HIV RNA and CD4 lymphocyte counts in patients with uncontrolled HIV infection. J Infec Dis.2003;188:1804-1814.
  3. Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC, Hahn B, Hoxie JA, Hunter E, Korber B, Landay A, Lederman MM, Lieberman J, McCune JM, Moore JP, Nathanson N, Picker L, Richman D, Rinaldo C, Stevenson M, Watkins DI, Wolinksy SM, Zack JA. A sound rationale needed for phase III HIV-1 vaccine trials. Science.2004;303(5656):316.
  4. Al-Harthi L, Voris J, Patterson BK, Becker S, eron J, Smith KY, Mildvan D, D’Amico R, Snidow J, Pobiner B, Yau L, Landay A. Evaluation of immune reconstitution parameters in antiretroviral-naive patients: Role of the thymus in immune recovery. HIV Medicine. 2004;5(1):55-65.
  5. Lange CG, Xu Z, Patterson BK, Medvik K, Harnisch B, Asaad R, Valdez H, Lee SJ, Landay A, Lieberman J, Lederman MM. Proliferation responses to HIV p24 during antiretroviral therapy do not reflect improved immune phenotype or function. AIDS.2004;18(4):605-613.
  6. Mildvan D, Bosch R, Kim RS, Spritzler J, Haas DW, Kuritzkes D, Kagan J, Nokta M, DeGruttola V, Moreno M, Landay A. Immunophenotypic markers and antiretroviral therapy (IMART): T-cell activation and maturation help predict treatment response. J Infec Dis. 2004;189(10):1811-1820.
  7. Winchester R, Pitt J, Magder LS, Goring HH, Landay A. Mother-to-child transmission of HIV-1: Strong association with certain maternal HLA-B alleles independent of viral load implicates innane immune mechanisms. J Acquir Immune Defic Syndr. 2004;36(2):659-670.
  8. Bahbouhi B, Landay A, and Al-Harthi L. Dynamics of cytokine expression within HIV productively infected primary CD4+ T cells. Blood. 2004;103(12):4581-4587.
  9. Lurain NS, Robert ES, Xu J, Camarca M, Landay A, Kovacs AA, Reichelderfer PS. Human immunodeficiency virus type 1 and cytomegalovirus co-infection in the female genital tract. J Infec Dis. 2004;190(3):619-623.
  10. Smith K, Aga E, Bosch RJ, Valdez H, Connick E, Landay A, Kuritzkes D, Gross BH, Francis IR, McCune JM, Kessler H, Lederman M. Long-term changes in circulating CD4 T lymphocytes in virologically supressed patients after 6 years of highly active antiretroviral therapy. AIDS. 2004;18(14):1953-1956.